🇺🇸 FDA
Patent

US 11384065

Heterocyclic compound as CSF-1R inhibitor and use thereof

granted A61KA61K31/4035A61K9/0019

Quick answer

US patent 11384065 (Heterocyclic compound as CSF-1R inhibitor and use thereof) held by Medshine Discovery Inc. expires Mon Jul 07 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Medshine Discovery Inc.
Grant date
Tue Jul 12 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jul 07 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
19
CPC classes
A61K, A61K31/4035, A61K9/0019, A61K9/0053, A61P